Our study has shown that sarcopenia could be a negative prognostic factor in patients with metastatic ER+/HER2- BC treated with CDK 4/6 inhibitors (Figure 3), in accordance with the aforementioned recent study by Franzoi (43). Here, ERBB2 is linked to sarcopenia.